Edwin J C G van den Oord1, Patrick F Sullivan. 1. Virginia Institute for Psychiatric and Behavioral Genetics, Medical College of Virginia/Virginia Commonwealth University, PO Box 980126, Richmond, VA 23298-0126, USA. ejvandenoord@vcu.edu
Abstract
OBJECTIVES: To develop a method for designing studies to find disease mutations that can achieve a set of goals with respect to proportions of false and true discoveries with the minimum amount of genotyping. METHODS: Derivation of an analytical framework supplemented with simulation techniques. The approach is illustrated for a fine mapping study and a whole-genome linkage disequilibrium scan. RESULTS: The use of multiple stages where earlier stages are characterized by very high false discovery rates (FDR) followed by an abrupt change to the required FDR in the final stage results in a 50-75% reduction in genotyping. The proportion of true discoveries is a much more important determinant of the genotyping burden than the FDR. Neither sample size nor controlling the false discoveries will present major problems in whole-genome LD scans but the amount of genotyping will be extremely large even if the study is completely designed to minimize genotyping. CONCLUSIONS: The proposed statistical framework presents a simple and flexible approach to determine the design parameters (e.g. sample size, p values at which tests need to be performed at each stage) that minimize the genotyping burden given a set of goals for the percentage of true and false discoveries. Copyright 2003 S. Karger AG, Basel
OBJECTIVES: To develop a method for designing studies to find disease mutations that can achieve a set of goals with respect to proportions of false and true discoveries with the minimum amount of genotyping. METHODS: Derivation of an analytical framework supplemented with simulation techniques. The approach is illustrated for a fine mapping study and a whole-genome linkage disequilibrium scan. RESULTS: The use of multiple stages where earlier stages are characterized by very high false discovery rates (FDR) followed by an abrupt change to the required FDR in the final stage results in a 50-75% reduction in genotyping. The proportion of true discoveries is a much more important determinant of the genotyping burden than the FDR. Neither sample size nor controlling the false discoveries will present major problems in whole-genome LD scans but the amount of genotyping will be extremely large even if the study is completely designed to minimize genotyping. CONCLUSIONS: The proposed statistical framework presents a simple and flexible approach to determine the design parameters (e.g. sample size, p values at which tests need to be performed at each stage) that minimize the genotyping burden given a set of goals for the percentage of true and false discoveries. Copyright 2003 S. Karger AG, Basel
Authors: Jeroen P Koning; Jelle Vehof; Huibert Burger; Bob Wilffert; Asmar Al Hadithy; Behrooz Alizadeh; Peter N van Harten; Harold Snieder Journal: Psychopharmacology (Berl) Date: 2011-07-13 Impact factor: 4.530
Authors: P F Sullivan; D Lin; J-Y Tzeng; E van den Oord; D Perkins; T S Stroup; M Wagner; S Lee; F A Wright; F Zou; W Liu; A M Downing; J Lieberman; S L Close Journal: Mol Psychiatry Date: 2008-03-18 Impact factor: 15.992
Authors: D E Adkins; K Aberg; J L McClay; J Bukszár; Z Zhao; P Jia; T S Stroup; D Perkins; J P McEvoy; J A Lieberman; P F Sullivan; E J C G van den Oord Journal: Mol Psychiatry Date: 2010-03-02 Impact factor: 15.992
Authors: J L McClay; D E Adkins; K Aberg; S Stroup; D O Perkins; V I Vladimirov; J A Lieberman; P F Sullivan; E J C G van den Oord Journal: Mol Psychiatry Date: 2009-09-01 Impact factor: 15.992
Authors: John M Hettema; Seon-Sook An; Jozsef Bukszar; Edwin J C G van den Oord; Michael C Neale; Kenneth S Kendler; Xiangning Chen Journal: Biol Psychiatry Date: 2008-04-23 Impact factor: 13.382
Authors: A H Fanous; Z Zhao; E J C G van den Oord; B S Maher; D L Thiselton; S E Bergen; B Wormley; T Bigdeli; R L Amdur; F A O'Neill; D Walsh; K S Kendler; B P Riley Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2010-03-05 Impact factor: 3.568
Authors: Liisa Tomppo; William Hennah; Päivi Lahermo; Anu Loukola; Annamari Tuulio-Henriksson; Jaana Suvisaari; Timo Partonen; Jesper Ekelund; Jouko Lönnqvist; Leena Peltonen Journal: Biol Psychiatry Date: 2009-02-28 Impact factor: 13.382
Authors: P F Sullivan; E J C de Geus; G Willemsen; M R James; J H Smit; T Zandbelt; V Arolt; B T Baune; D Blackwood; S Cichon; W L Coventry; K Domschke; A Farmer; M Fava; S D Gordon; Q He; A C Heath; P Heutink; F Holsboer; W J Hoogendijk; J J Hottenga; Y Hu; M Kohli; D Lin; S Lucae; D J Macintyre; W Maier; K A McGhee; P McGuffin; G W Montgomery; W J Muir; W A Nolen; M M Nöthen; R H Perlis; K Pirlo; D Posthuma; M Rietschel; P Rizzu; A Schosser; A B Smit; J W Smoller; J-Y Tzeng; R van Dyck; M Verhage; F G Zitman; N G Martin; N R Wray; D I Boomsma; B W J H Penninx Journal: Mol Psychiatry Date: 2008-12-09 Impact factor: 15.992